Journal article

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Stephen P Mulligan, Devinder Gill, Gavin Cull, Leanne Berkahn, David Simpson, Philip Campbell, Rosemary Anne Harrup, Naomi J Mackinlay, Constantine S Tam, Xavier Badoux, Oliver Giles Best, Bryone Jean Kuss

Blood | American Society of Hematology | Published : 2018


Abstract BACKGROUND: Immunochemotherapy (ICT) with fludarabine (F), cyclophosphamide (C) and rituximab (R) provides prolonged progression free (PFS) and overall survival (OS) in fit younger patients with CLL. The Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 study previously showed FCR based therapy was safe, tolerable and effective in fit older CLL patients. We now assess the PFS and OS status by treatment arm and mutational status after a minimum of 5 years following final recruitment. METHODS: Previously untreated patients with progressive CLL aged ≥65 were randomised to one of three treatment regimens FR5, FCR3 and FCR5 (= full dose) as follows: (i) ..

View full abstract